SHR-1139 NCT07758075 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 11 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 2

Clinical phase

Not yet recruiting

Recruitment status

50

Planned enrollment

2027-07-01

Primary-completion proxy

Executive view

NCT07758075 evaluates SHR-1139 in Plaque psoriasis. The disclosed sponsor is Guangdong Hengrui Pharmaceutical Co., Ltd., the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is The proportion of participants with a sPGA response of 0 or 1 at week 16., assessed over at week 16.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07758075 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Plaque psoriasis landscape. Drug & Asset MCP drug_fetch was queried for SHR-1139, while Company & Deal Intelligence MCP organization_fetch was queried for Guangdong Hengrui Pharmaceutical Co., Ltd..

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07758075	SHR-1139	Phase 2 / Not yet recruiting	Guangdong Hengrui Pharmaceutical Co., Ltd.	China	The proportion of participants with a sPGA response of 0 or 1 at week 16. at week 16	2027-07-01
NCT07801495	MRT-6160	Phase 2 / Not yet recruiting	Novartis Pharmaceuticals	Geography not reported	Part A: Number of participants achieving American College of Rheumatology 50 (ACR50) response Week 12	2028-12-13
NCT07802964	HRS-4139	Phase 1 / Not yet recruiting	Fujian Suncadia Pharmaceuticals Co Ltd.	China	Adverse events (AEs) Evaluation was performed up to Day 36 or Day 72.	2027-03-01
NCT07792928	HCXT-2001	Phase 1 / Not yet recruiting	Sponsor not reported	New Zealand	Number of participants with AEs,SEAs, with abnormal - vital signs,physcial examinations,clinical laboratory results ,12… Day 1 to Day 50	2026-11-10
NCT07780929	Calcipotriene	Not Applicable / Recruiting	Xijing Hospital	China	Observation of the changes in the phenotypes of psoriasis lesions before and after treatment using dermoscopy From enrollment to the end of treatment at 4 weeks	2026-08-30

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07758075 is a Phase 2, not yet recruiting study with 50 planned participants. Allocation is Randomized, masking is Triple, and the intervention model is Parallel Assignment.

The primary endpoint is “The proportion of participants with a sPGA response of 0 or 1 at week 16.” over “at week 16.” No additional primary-endpoint description was returned in the selected field set.

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 50 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Plaque psoriasis. These records do not establish direct evidence for NCT07758075 unless the registration number matches.

Real-world outcomes of deucravacitinib in Chinese plaque psoriasis patients: a 24-week prospective study

Phase 4; n=101; PASI75(24-week) = 77.2 % Source: https://pubmed.ncbi.nlm.nih.gov/41769731/

A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects With Chronic Plaque Psoriasis

Phase 3; n=337; Percentage of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs) = 26.1 percentage of participants ; Percentage of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs) = 33.3 percentage of participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04286607

Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Padagis' Roflumilast Cream 0.3% to Arcutis's Zoryve™ (Roflumilast Cream 0.3%) Cream and…

Phase 3; n=416; IGA = 78 Participants ; IGA = 79 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05763082

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

SHR-1139 is indexed as Bispecific antibody with IL-23p19 x IL-36R biology and a global stage of Phase 2. The asset profile lists Guangdong Hengrui Pharmaceutical Co., Ltd. as an originator or developer.

No exact Company & Deal Intelligence profile was returned for Guangdong Hengrui Pharmaceutical Co., Ltd.. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether SHR-1139 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07758075
Protocol source: https://clinicaltrials.gov/study/NCT07758075
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 11 September 2026.

SHR-1139 in Plaque psoriasis is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes The proportion of participants with a sPGA response of 0 or 1 at week 16. and 2027-07-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP